Early effectivity of Teduglutide for the Treatment of short bowel Syndrome – our first Clinical experience

Gombošová Laura1, Krivuš Juraj2, Lazúrová Ivica1, Dedinská Ivana2, Mokáň Marián2

1Internal clinic of University Hospital of Martin and Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia
2Transplant center of University Hospital of Martin and Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia

*Corresponding author: Krivuš Juraj MD, University Hospital, Kollárova 2, 03601 Martin, Slovakia.

Received date: June 28, 2021; Accepted date: July 14, 2021; Published date: July 19, 2021

Citation: Gombošová Laura, Krivuš Juraj, Lazúrová Ivica, Dedinská Ivana, Mokáň Marián, (2021) Early effectivity of Teduglutide for the Treatment of short bowel Syndrome – our first Clinical experience. J. Archives of Medical Case Reports and Case Study, 4(3); DOI:10.31579/2692-9392/068

Copyright: © 2021 Krivuš Juraj, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Short bowel syndrome is an uncommon malabsorptive condition most frequently caused by massive surgical resection of the small intestine. Standard of care is home parenteral nutrition. Teduglutide, glucagon like peptide 2 analog, was approved to treat patients with short bowel syndrome, who are stable following a period of post-surgery intestinal adaptation.

We report two cases of patients with short bowel syndrome on home parenteral nutrition, treated with teduglutide, novel advanced therapy. We monitored the effectiveness and tolerance of the new treatment.

Teduglutide increases intestinal absorption, causes cryptal hyperplasia, villous hypertrophy, angiogenesis, and allows weaning from parenteral nutrition. We confirmed the early onset of treatment effectiveness in the 4th month. Early effectiveness of treatment allowed a reduction in the volume of home parenteral nutrition with an improvement in quality of life.

Key words: short bowel syndrome; teduglutide; glucagon like peptide 2; home parenteral nutrition

Introduction

Short bowel syndrome (SBS) is an uncommon malabsorptive condition most frequently caused by massive surgical resection of the small intestine due to Crohn’s disease, mesenteric ischemia, adhesive ileus or traumatic conditions. [1, 2]. SBS is associated with significant morbidity and mortality, reduced quality of life, and high healthcare costs. [1]. The clinical manifestations are only partially related with the length of the resected intestine. It depends on the ability of the residual gastrointestinal tract to compensate the resected part and to adapt functionally to the new anatomical condition [2]. SBS belongs to intestinal failure, defined as the reduction of the gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes. [2]. Home parenteral nutrition (HPN) is the primary life-saving therapy for patients with chronic intestinal failure due to benign and malignant diseases [3]. Chronic IF treated with HPN may be associated with life-threatening complications of either the underlying disease or HPN, the latter accounting for around 14% of total deaths such as venous catheter-related complications and intestinal failure associated liver disease. [4]. Novel therapy of SBS is teduglutide, recombinant analog of enteral hormone glucagon-like peptide 2. It promotes intestinal growth, facilitates natrium recirculation, considered the primary mechanism by which many nutrients such as sugars and amino acids are absorbed. Therapy with teduglutide allows weaning from HPN with enteral autonomy onset. [5]. In a phase-III trial on adults with SBS dependent on HPN, a significantly greater proportion of patients taking 0.05 mg/kg/day teduglutide than placebo recipients achieved a ≥20% reduction in weekly HPN volume from baseline to week 20 and maintained it to week 24. [6]. Teduglutide is contraindicated in patients with active gastrointestinal malignancy, including those with nongastrointestinal malignancies. [6, 9]. Colonoscopic examination and removal of any colorectal polyps is recommended within 6 months prior to initiation of teduglutide. Subsequently, surveillance colonoscopy is recommended at the end of 1 year and then every 5 years or more frequently as needed. [7]. The aim of
the article is to demonstrate the early efficacy of teduglutide with adjustment of weaning from parenteral nutrition.

**Case presentations**

**Patient information, 1.st case**

Patients history: a 54-year-old woman without a relevant medical history suffered a car accident in 2016. The result was severe destructive injury to the skeleton and abdominal organs. She underwent surgery with small and large bowel resection ileostomy with no colon-in-continuity was constructed, I-type of short bowel syndrome. The rest of the small intestine is about 60 cm, resection of the large intestine with the rest 40 cm, blinded.

We indicated HPN and hydration: all in one nutrition bag with 1710 kcal/1075 ml for 10 hours daily in the week (7/7), 1000 ml of balanced salt solution 7/7 via Hickmans catheter and medication to slow the passage through the digestive tract and reduce the secretion of digestive juices.

The woman experienced several complications in a short time. The first one was thrombosis of an upper hollow vein and the internal jugular vein, in January 2017. The catheter had to be extracted and immediately inserted into the femoral vein, low molecular heparin treatment was recommended. After partial recanalization of the affected vessels Hickmans catheter was inserted into the left subclavian vein. Next complication was recurrent catheter sepsis (blood cultivation for *Staphylococcus aureus*), with preserved catheter treated with amoxicilnine clavulanae, in 2018. Within two years, there was a partial adaptation of the intestine with reduced infusions form 3/7 to 5/7. In 2020, patient developed spondylodiscitis leading to the need to increase HPN to 7/7 plus 5/7 rehydration therapy.

Indication for teduglutide: after the antibiotic therapy of spondylodiscitis was patient indicated for the treatment with teduglutide with daily dose 0.26 ml (2.6 mg) subcutaneously. During therapy, we noted the prolapse of the stoma without further progression. The patient complains of fatigue, anorexia, bloating, stomach hardening. After changing the dosing time to the evening, the patient has no problems. After 20 weeks of treatment, we gradually reduced HPN more than 35% and total parenteral substitution by 25.6%. Patient requires HPN only 3 times a week rehydration support as she needed. The patient’s laboratory results are stable.

Outcomes of treatment: after 20 weeks, we evaluated the treatment as effective. At 40th week of treatment, the patient could be completely weaned from parenteral support. Oral feeding was effective. The patient's quality of life has significantly improved. She is not dependent on infusions, she can eat normally.

**Case presentation**

**Patient information, 2.nd case**

Patients history: 59 years old man with negative medical history was suffered from adhesive ileus, in 2017 year. Histological examination confirmed fibrinous purulent visceral peritonitis of unclear etiology. The condition required urgent surgical treatment, subtotal intestinal resection (60 cm rest of small intestine) with right sided hemicolecctomy was performed. Type II. short bowel syndrome has developed, without ostomy, with colon in continuity.

Home parenteral nutrition 1500 kcal together with 1000 ml of balanced solutions was started. Parenteral nutrition with oral hyperphagia 2500 kcal daily was combined, with metabolic and water homeostasis, without complications, without weight loosing. After two years (in 2019) recurrent catheter-related sepsis was diagnosed (*Staphylococcus aureus*).

Sepsis was treated with antibiotics and cathether replacement. The patient works full time and HPN with daily infusion regime is limiting for him. Indication for teduglutide therapy: treatment with glukagon like peptide 2 analog was indicated (in the time of teduglutide registration in our country, in November 2020). Screening colonoscopy is a mandatory examination before teduglutide treatment. Colonoscopy revealed tubulovilous adenomatous polypl, endoscopic polypectomy was performed. Teduglutide dose adjusted to weight was 0.32ml/3.2 mg once daily, subcutaneously. Abdominal pain and bloating occurred during the first month of treatment, with resolution later. In the fifth month of treatment we registered a reduction in diarrhea (from 7 to 3 bowel movements), stool thickening, increased diuresis without oedemas.

Outcomes of treatment: Reduction of the volume of parenteral substitution was possible from 7/7 to 4/7 (43% reduction) with balanced water and mineral homeostasis. We anticipate further reduction of parenteral support with possible weaning from HPN and improving the quality of life. Also in this patients we evaluate the treatment as effective. At 28 weeks of treatment, it was possible to further reduce the parenteral support to 3 infusions per week (regime 3/7, 58% reduction in parenteral substitution from the start of HPN). It is assumed that it will be possible to terminate parenteral feeding in a short time.

**Discussion**

Teduglutide, glucagon like peptide 2 analog, was approved to treat patients with short bowel syndrome, who are stable following a period of post-surgery intestinal adaptation Teduglutide has demonstrated clinical effectiveness in real-world studies. [9]. Our first clinical experiences confirms the onset of early effectiveness of treatment, with mild self limited adverse events at the beginning. Both patients reported stool thickening, reduced bowel movements (reduced stoma output), loss of thirst, and increased diuresis. According real life experiences improved stool consistency and frequency, as well as the sensation of thirst, were identified as early clinical markers of response. [8]. Reductions in parenteral support requirements were accompanied by significant increases in mean villus height and crypt depth in this cohort as assessed by direct measurement of biopsies obtained during endoscopy [9]. HPN volume reductions were associated with improvements in quality of life scores for patients with short bowel syndrome treated with teduglutide [10]. During further treatment, we anticipate weaning our patients from HPN. This is a great advantage for a full time working patient. We preliminarily assess that teduglutide treatment is effective and safe for patients with short bowel syndrome. Hypertrophy of ostomy was not progressed. Integrated safety data for 222 person-years of exposure to teduglutide in four clinical trials demonstrated that teduglutide has a safety profile in adult patients with SBS–IF consistent with prior studies. [9]. Teduglutide was associated with a significantly increased risk of gastrointestinal stoma complication compared with placebo. Stoma enlargement was observed in clinical trials and in real-world clinical practice [9].

**Conclusion**

Treatment for short bowel syndrome is well advanced. An innovative treatment is teduglutide, which allows weaning from parenteral nutrition and relieves the patient of a large number of infusion bags and medical devices. In practice, we have confirmed the early onset of effectiveness of GLP2 treatment. Therapy is well tolerated, with mild adverse events (abdomen pain) in the start of therapy. Significantly improves the quality of life of patients.

**Contributions**

LG and JK performed the data collection. LG drafted the initial manuscript. JK, ID reviewed and IL revised the manuscript. ID and MM
contributed to the conception of the manuscript and interpretation of the data, critically reviewed and revised the manuscript. IL coordinated and supervised data collection, reviewed and revised the manuscript. All authors took care of the patient and approved the final manuscript as submitted and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Conflict of interests
Authors declare no conflicts of interest.

Availability of data and materials
All data supporting the findings of this article are included in the manuscript.

Abbreviations:
SBS – short bowel syndrome
HPN - home parenteral nutrition
IF- intestinal failure
7/7 – administration of i.v. nutrition 7 days a week

Ethics declarations
Ethics approval and consent to participate. Not applicable.

Consent for publication
Written informed consent was obtained from the patient’s legal guardians for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interest to disclose.

Acknowledgements: Not applicable

Funding: No funding was secured for this study.

References